Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals (ARWR) is the lead sponsor of 16 active clinical trials listed on ClinicalTrials.gov^[4], including 7 Phase 3^[1], 7 Phase 2^[2], 8 Phase 1^[3].

Trial NCT06822790^[5] evaluates Plozasiran Injection in Hypertriglyceridemia with a target enrollment of 869 participants. Trial NCT05089084^[6] evaluates Plozasiran in Familial Chylomicronemia with a target enrollment of 75 participants. Trial NCT07037771^[7] evaluates zodasiran Injection in Homozygous Familial Hypercholesterolemia with a target enrollment of 60 participants.

No Form 4 insider filings for ARWR were recorded at the SEC in the past 30 days^[8].